Login
Super Investors BURRAGE CAPITAL MANAGEMENT LLC
BC

BURRAGE CAPITAL MANAGEMENT LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
—
Positions
1
Quarter ended
September 30, 2021
Filed
November 15, 2021

Reported portfolio value by quarter (8 quarters reported)

$149M —
Q4 19 Q2 20 Q4 20 Q2 21 Q3 21

$149M in Q4 2019 → — now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
0 0 NaN% New 0 —

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.

Q3 2021

quarter ended September 30, 2021 · filed November 15, 2021

Company Action Shares changed Value of change % of portfolio
Biocryst Pharmaceuticals Inc Exited −864,916 −$13.7M —
Intellia Therapeutics Inc Exited −63,634 −$10.3M —
E Epizyme Inc Exited −836,802 −$6.95M —
Essa Pharma Inc Exited −237,442 −$6.78M —
Neogenomics Inc Exited −147,921 −$6.68M —
MP Mei Pharma Inc Exited −2,331,313 −$6.64M —
CP Crinetics Pharmaceuticals In Exited −294,620 −$5.55M —
Cytokinetics Inc Exited −244,673 −$4.84M —
Amicus Therapeutics Inc Exited −500,000 −$4.82M —
HB Harmony Biosciences Hldgs In Exited −150,000 −$4.23M —

Showing the 10 largest of 23 changes.

Q2 2021

quarter ended June 30, 2021 · filed August 16, 2021

Company Action Shares changed Value of change % of portfolio
Protalix Biotherapeutics Inc Exited −2,125,585 −$9.48M —
Ptc Therapeutics Inc Exited −160,372 −$7.59M —
TP Turning Point Therapeutics I Trimmed −70,000 −$5.47M 0.2%
Amicus Therapeutics Inc New +500,000 +$4.82M 4.8%
CT Cara Therapeutics Inc Exited −180,000 −$3.91M —
Fulcrum Therapeutics Inc Exited −319,819 −$3.77M —
T Tricida Inc Exited −658,877 −$3.49M —
Apellis Pharmaceuticals Inc Exited −80,727 −$3.46M —
Verastem Inc New +705,585 +$2.87M 2.9%
E Epizyme Inc Added +272,247 +$2.26M 7.0%

Showing the 10 largest of 16 changes.

Q1 2021

quarter ended March 31, 2021 · filed May 17, 2021

Company Action Shares changed Value of change % of portfolio
IB Iveric Bio Inc Exited −1,388,136 −$9.59M —
Essa Pharma Inc New +237,442 +$6.9M 5.6%
Insmed Inc Exited −154,562 −$5.15M —
HB Harmony Biosciences Hldgs In New +150,000 +$4.96M 4.0%
Aurinia Pharmaceuticals Inc Exited −336,384 −$4.65M —
FT Frequency Therapeutics Inc Exited −124,650 −$4.4M —
CT Cara Therapeutics Inc New +180,000 +$3.91M 3.2%
T Tricida Inc New +658,877 +$3.49M 2.8%
E Epizyme Inc Trimmed −365,912 −$3.19M 4.0%
Geron Corp New +1,912,673 +$3.02M 2.4%

Showing the 10 largest of 30 changes.

Q4 2020

quarter ended December 31, 2020 · filed February 12, 2021

Company Action Shares changed Value of change % of portfolio
AT Aimmune Therapeutics Inc Exited −332,546 −$11.5M —
Protalix Biotherapeutics Inc New +2,470,332 +$8.97M 6.8%
Biocryst Pharmaceuticals Inc New +1,105,673 +$8.24M 6.3%
Orthopediatrics Corp Exited −171,607 −$7.88M —
Anaptysbio Inc Exited −330,549 −$4.88M —
Inozyme Pharma Inc New +170,796 +$3.53M 2.7%
Intellia Therapeutics Inc New +64,079 +$3.49M 2.7%
Assembly Biosciences Inc Exited −200,000 −$3.29M —
Regenxbio Inc Exited −116,405 −$3.2M —
Mirum Pharmaceuticals Inc New +161,628 +$2.82M 2.2%

Showing the 10 largest of 33 changes.

Q3 2020

quarter ended September 30, 2020 · filed November 13, 2020

Company Action Shares changed Value of change % of portfolio
AC Avrobio Inc Com Exited −225,900 −$3.94M —
Assembly Biosciences Inc New +200,000 +$3.29M 2.6%
AB Adverum Biotechnologies Inc Com Exited −156,012 −$3.26M —
T Tricida Inc New +188,182 +$1.71M 1.3%
G1 Therapeutics Inc Trimmed −145,279 −$1.68M 2.1%
Aurinia Pharmaceuticals Inc Added +105,945 +$1.56M 4.2%
FT Frequency Therapeutics Inc Trimmed −69,776 −$1.34M 2.0%
E Epizyme Inc Added +111,251 +$1.33M 9.4%
Z Zogenix Inc Trimmed −30,811 −$553K 0.6%
Ptc Therapeutics Inc Trimmed −5,841 −$273K 6.4%

Showing the 10 largest of 21 changes.

Q2 2020

quarter ended June 30, 2020 · filed August 14, 2020

Company Action Shares changed Value of change % of portfolio
AT Adc Therapeutics Sa Shs Isin#ch0499880968 New +134,912 +$6.32M 4.4%
FT Fulcrum Therapeutics Inc Com New +291,645 +$5.33M 3.7%
AT Aimmune Therapeutics Inc Com Added +220,000 +$3.68M 3.9%
Cytomx Therapeutics Inc Exited −482,982 −$3.46M —
CT Cara Therapeutics Inc Exited −258,766 −$3.29M —
T Tricida Inc Exited −131,661 −$2.78M —
IC Insmed Inc Com Par 01 Added +100,000 +$2.75M 3.2%
MB Merus B V Com Isin#nl0011606264 New +140,176 +$2.26M 1.6%
Xenon Pharmaceuticals Inc Exited −200,000 −$2.11M —
YT Y-mabs Therapeutics Inc Com Trimmed −48,763 −$2.11M 3.7%

Showing the 10 largest of 26 changes.

Q1 2020

quarter ended March 31, 2020 · filed May 14, 2020

Company Action Shares changed Value of change % of portfolio
A Arqule Inc Exited −595,018 −$11.9M —
Ascendis Pharma A/s Exited −43,775 −$6.09M —
Deciphera Pharmaceuticals Inc Exited −59,818 −$3.72M —
Cytokinetics Inc New +318,273 +$3.61M 3.6%
Regenxbio Inc New +115,000 +$3.54M 3.5%
A Avrobio Inc New +225,900 +$3.27M 3.2%
TP Turning Pt Therapeutics Inc New +77,172 +$3.25M 3.2%
Us Physical Therapy Inc Exited −21,500 −$2.46M —
DP Dicerna Pharmaceuticals Inc Exited −104,047 −$2.29M —
Xenon Pharmaceuticals Inc New +200,000 +$2.11M 2.1%

Showing the 10 largest of 37 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support